Bank of America Corp DE lifted its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 36.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 247,107 shares of the company's stock after purchasing an additional 66,138 shares during the quarter. Bank of America Corp DE owned about 0.31% of Viridian Therapeutics worth $4,737,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also made changes to their positions in the company. R Squared Ltd bought a new position in Viridian Therapeutics in the 4th quarter worth about $26,000. Foresite Capital Management VI LLC acquired a new position in shares of Viridian Therapeutics during the fourth quarter worth approximately $38,000. AlphaQuest LLC grew its holdings in Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after buying an additional 1,519 shares in the last quarter. Summit Investment Advisors Inc. increased its position in Viridian Therapeutics by 24.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after acquiring an additional 1,516 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in Viridian Therapeutics in the 4th quarter valued at approximately $164,000.
Viridian Therapeutics Stock Down 1.3%
NASDAQ VRDN traded down $0.18 during trading on Friday, reaching $13.79. The company's stock had a trading volume of 768,725 shares, compared to its average volume of 1,192,614. The stock has a market capitalization of $1.13 billion, a PE ratio of -3.20 and a beta of 0.57. The business has a 50-day moving average price of $13.02 and a 200-day moving average price of $16.45. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 1-year low of $9.90 and a 1-year high of $27.20.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm's revenue for the quarter was up .0% on a year-over-year basis. On average, research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on the company. The Goldman Sachs Group decreased their price target on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Royal Bank of Canada cut their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Needham & Company LLC restated a "buy" rating and issued a $36.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, May 20th. JMP Securities cut their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Finally, HC Wainwright restated a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, Viridian Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $36.70.
Read Our Latest Stock Report on Viridian Therapeutics
About Viridian Therapeutics
(
Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Featured Articles
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
